Pieris Pharmaceuticals

(NASDAQ: PIRS)
Healthcare  |  Biotechnology
3.87 0.03 0.78%
Stock Price | Nov. 15, 2019, 4 p.m.
1 Follower
Bid: 0.0
Ask: 0.0
Prev. Close: 3.84
52 Week Low: 2.39
52 Week High: 6.04
PE Ratio: 0.0
Dividend Yield: 0.0%

Company Summary

Pieris Pharmaceuticals Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of Anticalin class of biotherapeutics. Anticalin proteins are engineered versions of lipocalins, human proteins that naturally bind, store and transport a wide spectrum of molecules. The company with the help of technology creates differentiated drugs such as PRS-080, PRS-060, PRS-343 and PRS-332 that can help patients suffering from cancer, severe asthma, anemia, and other medical conditions with a high unmet medical need. Geographically, all the operation of the firm is functioned through the region of United States.

Read more Read less

Recently Viewed Tickers

Premium Stock Watchlist 05/20/2016

3 years ago

Premium Stock Watchlist 11/04/2015

4 years ago

Premium Stock Watchlist 11/02/2015

4 years ago

Premium Stock Watchlist 10/01/2015

4 years ago